The role of incretin-based therapies. including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized. along with significant cardiovascular (CV) benefits. https://www.socialstudiesscholar.com/